Fulgent Genetics ( (FLGT) ) has released its Q1 earnings. Here is a breakdown of the information Fulgent Genetics presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Fulgent Genetics, Inc. is a technology-based company specializing in laboratory services and therapeutic development, primarily in the healthcare sector, with a focus on precision medicine and cancer treatment. In its first quarter of 2025, Fulgent Genetics reported a core revenue growth of 16% year-over-year, achieving $73.5 million, while maintaining its full-year revenue guidance of $310 million. Despite a GAAP loss of $11.5 million, the company recorded a non-GAAP income of $1.2 million. The company ended the quarter with a strong cash position of $814.6 million. Key financial metrics include a GAAP loss per share of $0.37 and a non-GAAP income per share of $0.04. The company also repurchased approximately 516,000 shares, reflecting its ongoing commitment to shareholder value. Looking ahead, Fulgent Genetics remains optimistic about its growth prospects, with management expressing confidence in the momentum of its laboratory services and therapeutic development pipeline, while reiterating its financial guidance for the year.